Latest News

Novo Nordisk, a maker of Wegovy, says that the rapid growth is driving up emissions.

The company announced on Wednesday that Novo Nordisk's emissions will grow by 23% in 2024 and continue to rise through the end decade, as the company increases production of its blockbuster weight loss drug Wegovy.

As demand for Wegovy increases, the company spends billions of dollars to increase its production.

In an interview, Katrine DiBona (corporate vice president for global public affairs and Sustainability at Novo Nordisk) said that "Emissions are a result of growth."

The Danish pharmaceutical company said that its plans for expansion do not alter its commitment to its 2045 goal of net zero emissions, which it set in 2020.

It also announced a interim goal to reduce its Scope 3 emission by 33% from 2024, in its annual report released with its financial results for the fourth quarter on Wednesday.

The Scope 3 emissions, which includes all the suppliers in an organization's supply chain, account for 96% Novo's total.

Novo Nordisk plans to reduce emissions include switching to lower-carbon material where possible and setting expectations that suppliers use green power to deliver.

DiBona stated that some levers won't be available for a few years. The company therefore expects emissions will continue to rise until 2030. "It's going to get worse before it gets any better." It's important that we are very transparent about that.

Experts claimed that the company's interim goal seemed unrealistic since it did not decouple growth from emissions.

Sasja Beslik said, "Sounds a bit like a fairytale," in response to SDG Impact Japan's targets.

Beslik stated that companies are not at risk of losing their reputation if they set climate targets but fail to meet them.

Unfortunately, the sustainability aspect does not affect the financial results and is not included in the valuation of the stock.

Novo had previously reported that emissions increased by 55% from 2022-2023. However, it revised its accounting of emissions to restate 2023 data. (Reporting from Maggie Fick in London, and Alison Withers at Copenhagen; editing by Jan Harvey).

(source: Reuters)